Are amycretin and zenagamtide the same thing?

Yes. Zenagamtide is the international nonproprietary name assigned to the molecule previously referred to as amycretin. Novo Nordisk's own 2026 materials use both names, so you will encounter each in coverage.

How is this different from CagriSema?

Both engage GLP-1 and amylin pathways, but CagriSema is two separate molecules co-formulated (cagrilintide plus semaglutide), whereas amycretin is a single peptide that hits both receptors. The practical difference is pharmacokinetic simplicity and a single dose-response curve rather than two.

← All peptides

Weight & Metabolic

Clinical

Amycretin (Zenagamtide)

Also known as: Zenagamtide, Amycretin

Amycretin — now assigned the international nonproprietary name zenagamtide — is a single peptide that agonizes both the GLP-1 and amylin receptors, combining two distinct appetite pathways in one molecule.

Mechanism of Action

Amycretin is a unimolecular peptide agonist of both the GLP-1 receptor and the amylin receptor. Rather than co-formulating two drugs, a single molecule engages both pathways: GLP-1 receptor agonism drives incretin signaling, slowed gastric emptying and central appetite suppression, while amylin receptor agonism promotes satiation and suppresses post-prandial glucagon. Engaging both in one molecule is intended to produce additive metabolic effects with a simpler pharmacokinetic profile than a two-drug combination.

Half-life: Formulated for once-weekly subcutaneous administration; exact half-life not publicly characterized
Administration Routes: subcutaneous
Research Status: Clinical